PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1190805
PUBLISHER: Mordor Intelligence Pvt Ltd | PRODUCT CODE: 1190805
The Extracorporeal CO2 Removal Devices Market is projected to register a CAGR of 5.1% during the forecast period (2022-2027).
During the COVID-19 pandemic, the extracorporeal CO2 removal devices market was adversely affected due to supply chain issues. Various research and clinical trials have been conducted on the application of extracorporeal CO2 removal devices on COVID patients. For instance, in September 2021, a study was conducted to investigate the efficacy of extracorporeal CO2 removal for correction of hypercapnia in coronavirus disease 19 (COVID-19)-associated acute respiratory distress syndrome. According to the study, the prevalence of acute respiratory distress syndrome (ARDS) caused by COVID-19 is approximately 8%. Lung-protective ventilation is the current standard of care for ARDS. It limits lung and distal organ impairment but is associated with hypercapnia in approximately 14% of patients with mild to moderate ARDS and almost all patients with severe ARDS. In this setting, early implementation of an extracorporeal CO2 removal (ECCO2R) therapy may prevent further escalation of invasiveness of therapy (e.g., need for extracorporeal membrane oxygenation (ECMO)). A number of low-flow ECCO2R devices are now available, and some of those can be integrated into a renal replacement therapy (RRT) platform. Similarly, in September 2020, a research study was published titled "Extracorporeal multiorgan support including CO 2-removal with the ADVanced Organ Support (ADVOS) system for COVID-19: A case report" stated that in the context of secondary pulmonary infection and progressive liver failure, the patient had a sudden cardiac arrest. Irrespective of the outcome, the study concluded that extracorporeal CO2 removal and multiorgan support were feasible in the COVID-19-patients. Such clinical trials and studies would provide insight into the application of extracorporeal CO2 removal devices on COVID patients. Thus, the market is expected to grow overtime.
Increasing cases of respiratory emergencies and chronic obstructive pulmonary disease (COPD), and other diseases are the major factors augmenting the market growth. For instance, as per the September 2020 report from the University of Manchester students Emily Hammond and Charles McDonald, the estimated global prevalence of COPD was 552,300,599 people, of which 339,206,893 (8.58%) in Asia, 85,278,783 (8.52%) in the Americas, 64,298,051 (5.37%) in Africa, 59,484,329 (7.77%) in Europe and 4,032,543 (10.86%) in Oceania, and an estimated 57,991,563 people with COPD have been admitted to hospital annually. The increasing prevalence of other respiratory disorders such as asthma, cystic fibrosis, lung cancer, and others is further expected to complement the growth of the studied market over the years. For instance, according to the May 2021 update of the World Health Organization, asthma affected about 262 million people in 2019 all over the world and was responsible for about 461,000 deaths globally. According to the Globocan 2020 report, lung cancer was the second most prevalent cancer around the world, and in 2020, 2,206,771 new cases of lung cancer were diagnosed all over the world, and 1,796,144 people died because of it. Also, as per the same report, the five-year prevalence of lung cancer was 2,604,791 people in 2020.
Thus, the high incidence of chronic obstructive pulmonary diseases and other respiratory disorders around the world are expected to boost the growth in the market during the forecast period of the study.
Chronic obstructive pulmonary disease (COPD) is a progressive, life-threatening lung disease that causes breathlessness (initially with exertion) and predisposes to exacerbations. Moreover, serious illnesses may lead to the increasing need for emergency treatment for prolonged illnesses and protracted treatment associated with target diseases, and increasing cases of respiratory emergencies and chronic obstructive pulmonary disease (COPD) are the major factors driving growth in the market over the forecast period.
According to a research study published in February 2021, titled "Burden of COPD among population above 30 years in India: protocol for a systematic review and proposed meta-analysis", the estimated overall prevalence of COPD in the low- and middle-income countries was 9.2%, and meta-analysis revealed that the prevalence of COPD among the people of age 30 years and more was 10.6% in low- and middle-income countries.
Also, as per the June 2021 report of the World Health Organization, COPD was responsible for 3.23 million deaths in 2019 around the world, and about 80% of these deaths were reported in low- and middle-income countries, which suggests the high prevalence of COPD in the low- and middle-income countries and the high growth of the studied market is expected in these regions over the forecast period.
Thus, owing to the abovementioned factors, the market segment is expected to show considerable growth over the forecast period.
The extracorporeal CO2 removal devices market in North America is expected to grow owing to factors such as the COVID-19 pandemic, coupled with increasing incidences of respiratory disorders, COPD, increasing government initiatives, and a well-developed healthcare system.
As per the April 2021 statistics by the Asthma and Allergy Foundation of America, about 20 million adults aged 18 years or older in United States have asthma. Similarly, as per the 2021 estimates by Statistics Canada, in 2020, the number of people aged 35 to 49 years suffering from chronic obstructive pulmonary disease (COPD) disease was 57,300; 50 to 64 years was 285,300, and 65 years and above was 488,100. Thus, the prevalence of such disorders in these countries indicates a consistent demand for extracorporeal CO2 removal devices in the country, thereby contributing to the market growth in the region.
Similarly, clinical trials are one of the factors for the growth of the region. For instance, in September 2021, ALung Technologies, Inc., the leading provider of low-flow extracorporeal carbon dioxide removal (ECCO2R) technologies for treating patients with acute respiratory failure, enrolled 100 patients in United States-based VENT-AVOID pivotal trial. The VENT-AVOID pivotal trial is currently the world's largest trial ever conducted on the utilization of ECCO2R in AE-COPD, with 100 patients now enrolled. Such trials provide insight into the upcoming technologies and increased growth in the region.
Hence, due to the above-mentioned factors, the market is likely to grow in the future.
The Extracorporeal Co2 Removal devices market is moderately competitive and, in terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Medtronic, Getinge AB, Xenios AG, Alung Technologies, and ESTOR S.P.A, among others.